Alfie, who Duchenne Muscular Dystrophy, wants to walk on the pitch at a Liverpool FC game and watch a football match abroad.

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2025 and recent business highlights.

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...